A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
Running, not enrolling · Phase 2 · Has a placebo group
Conditions studied: Duchenne Muscular Dystrophy
In brief
The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a randomized, double-blind, placebo-controlled part A, followed by an open-label part B.
Key facts
- Study ID
- NCT05540860
- Run by
- Edgewise Therapeutics, Inc.
- People needed
- 76
- Starts
- 2022-10-24
- Expected to finish
- 2027-01-01
- Last updated by the study team
- 2025-11-12
Who can join
Age: 4 and older, up to 9. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Arkansas Children's Hospital — Little Rock, Arkansas, United States
- UCLA Medical Center — Los Angeles, California, United States
- UC Davis Medical Center — Sacramento, California, United States
- Children's Hospital Colorado — Aurora, Colorado, United States
- University of Florida — Gainesville, Florida, United States
- Rare Disease Research — Atlanta, Georgia, United States
- University of Iowa — Iowa City, Iowa, United States
- University of Kansas Medical Center — Kansas City, Kansas, United States
- Kennedy Krieger Institute — Baltimore, Maryland, United States
- University of Massachusetts Memorial Medical Center — Worcester, Massachusetts, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- Cincinnati Children's Hospital — Cincinnati, Ohio, United States
- Nationwide Children's Hospital — Columbus, Ohio, United States
- Cook Children's Medical Center — Fort Worth, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.